摘要
目的探究超声造影参数结合血清miR⁃214、miR⁃1296对甲状腺乳头癌(PTC)的诊断价值及其与肿瘤增殖、侵袭关系。方法选取2020年12月至2023年5月濮阳市人民医院收治的60例PTC患者、甲状腺腺瘤患者60例分别作为观察组、对照组。对比两组超声造影参数[峰值强度(PI)、平均通过时间(MTT)、达峰时间(TTP)、曲线下面积(AUC)]、血清miR⁃214、miR⁃1296表达,分析超声造影参数(PI、MTT、TTP、AUC)、血清miR⁃214、miR⁃1296表达与增殖、侵袭基因(PDCD4、ADAM9、PP4R1、BCORL1、TPX2、CXCR4)表达的关系,绘制受试者工作特征(ROC)曲线评价超声造影参数、血清miR⁃214、miR⁃1296表达对PTC的诊断价值。结果观察组PI、AUC及血清miR⁃1296表达低于对照组,TTP、MTT及血清miR⁃214表达高于对照组(P<0.05);Logistic回归分析显示,PI、AUC、miR⁃1296升高是PTC的保护因素,TTP、MTT、miR⁃214升高是PTC的危险因素(P<0.05);相关性分析显示,PTC患者PI、AUC及血清miR⁃1296表达与PDCD4、PP4R1表达呈正相关关系,与TPX2、ADAM9、BCORL1、CXCR4表达呈负相关关系,TTP、MTT及血清miR⁃214表达与PDCD4、PP4R1表达呈负相关关系,与TPX2、ADAM9、BCORL1、CXCR4表达呈正相关关系(P<0.05);PTC患者PI、AUC与血清miR⁃214表达呈负相关关系,与血清miR⁃1296表达呈正相关关系;TTP、MTT与血清miR⁃214表达呈正相关关系,与血清miR⁃1296表达呈负相关关系(P<0.05);ROC曲线结果显示,超声造影参数、血清miR⁃214、miR⁃1296表达联合诊断ROC曲线的AUC最大,且>0.9,具有良好诊断效能。结论超声造影参数、血清miR⁃214、miR⁃1296表达与PTC增殖及侵袭程度密切相关,联合检测可提高PTC的诊断效能。
Objective To explore the diagnostic value of contrast⁃enhanced ultrasound parameters combined with serum miR⁃214 and miR⁃1296 in the diagnosis of papillary thyroid carcinoma(PTC)and their relationship with tumor proliferation and invasion.Methods A total of 60 patients with PTC admitted to Puyang People's Hospital from December 2020 to May 2023 were selected as the observation group,and another 60 patients with thyroid adenoma admitted during the same period were selected as the control group.The ultrasound imaging parameters(peak intensity(PI),mean transit time(MTT),time to peak(TTP),area under the curve(AUC),proliferation,invasion genes(PDCD4,ADAM9,PP4R1,BCORL1,TPX2,CXCR4),and serum miR⁃214 and miR⁃1296 expression were compared between the two groups.The relationship between ultrasound imaging parameters[peak intensity(PI),mean transit time(MTT),time to peak(TTP),area under the curve(AUC)],serum miR⁃214 and miR⁃1296 expression,and proliferation,invasion genes(PDCD4,ADAM9,PP4R1,BCORL1,TPX2,CXCR4)expression was analyzed.The ROC curve was drawn to evaluate the diag⁃nostic value of ultrasound imaging parameters,serum miR⁃214,and miR⁃1296 expression for PTC.Results The PI,AUC,and serum miR⁃1296 expression in the observation group were lower than those in the control group,while the TTP,MTT,and serum miR⁃214 expression were higher than those in the control group,with statistically significant differences(P<0.05).Logistic regression analysis showed that the parameters of contrastenhanced ultrasound,serum miR⁃214,and miR⁃1296 expression were factors affecting PTC(P<0.05).The expression of PDCD4 and PP4R1 mRNA in the observation group was lower than that in the control group,while the expression of TPX2,ADAM9,BCORL1,and CXCR4 was higher than that in the control group,with statistically significant differences(P<0.05).Correlation analysis showed that the expression of PDCD4 and PP4R1 mRNA in PTC patients was positively correlated with PI,AUC,and serum miR⁃1296 expression,while negatively correlated with TPX2,ADAM9,BCORL1,and CXCR4 expression.The expression of TTP,MTT,and serum miR⁃214 was negatively correlated with PDCD4 and PP4R1 mRNA expression,while positively correlated with TPX2,ADAM9,BCORL1,and CXCR4 expression(P<0.05).In patients with PTC,PI,and AUC were negatively correlated with serum miR⁃214 expression and positively correlated with serum miR⁃1296 expression.TTP and MTT were positively correlated with serum miR⁃214 expression and negatively correlated with serum miR⁃1296 expression(P<0.05).The ROC curve results showed that the combined diagnosis of ultrasound imaging parameters,serum miR⁃214,and miR⁃1296 expression had the highest AUC of the ROC curve,which was greater than 0.9,indicating good diagnostic performance.Conclusion The parameters of contrastenhanced ultrasound,serum miR⁃214,and miR⁃1296 expression are closely related to the proliferation and invasion of PTC.Combined detection can improve the diagnostic efficacy of PTC.
作者
刘庆华
陈晓晓
任正君
LIU Qinghua;CHEN Xiaoxiao;REN Zhengjun(Thyroid and Breast Surgery Department of Puyang People's Hospital,Puyang,Henan,China,457001)
出处
《分子诊断与治疗杂志》
2025年第1期41-45,共5页
Journal of Molecular Diagnostics and Therapy
基金
河南省医学科技攻关计划项目(2021063229)。
